Other functions - preclinical in vitro and in vivo agent development assays - test the efficacy of a multi-antigen vaccine in the prevention of methylnitrosourea-induced mammary cancers in rats.

Ended Awarded Sep 20, 2012 Last action May 6, 2015

Contract number: HHSN26100002
Awardee: University Of Alabama At Birmingham UEI YND4PLMC9AN7
Awarding agency: National Cancer Institute National Institutes of Health, Department of Health and Human Services
Obligated: $669,243

Award facts

Contract value 100% obligated: $669,243.00 Current and potential, with all options
Completion date 100% complete: Sep 19, 2015 Current and potential, with all options
NAICS code: 541711 Research and Development in Biotechnology
PSC: AN11 Health R&D Services; Health Care Services; Basic Research
Set-aside: No set-aside
Competition: Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
Pricing: Cost No Fee
Place of performance: Birmingham, AL 35294, USA

Award details come from SAM.gov/FPDS.

Action	Obligated	Date
Other Administrative Action 6	$0	May 6, 2015
Other Administrative Action 5	$0	Feb 13, 2015
Other Administrative Action 4	$0	Sep 2, 2014
Other Administrative Action 3	$0	May 27, 2014
Other Administrative Action 2	$0	Nov 26, 2013
Other Administrative Action 1 · Other functions - efficacy of a multi-antigen vaccine in the prevention of methylnitrosourea-induced mammary cancers (ER+) in female sprague-dawley rats…	$0	May 20, 2013
Original award	$669,243	Sep 20, 2012

HHSN26100002 was awarded to University Of Alabama At Birmingham by National Cancer Institute (National Institutes of Health) on September 20, 2012.

The government has obligated $669,243 on HHSN26100002.

Yes. HHSN26100002 is a delivery order under HHSN261201200021I, an indefinite delivery contract, on Preclinical Agent Development Assays 2012-2016.

The extent of competition for HHSN26100002 was full and open competition. The government received 1 offer.

On GovTribe

Try for free Login